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Significance Statement This protocol provides a first tier screening model for detecting direct 
mitochondrial toxicity of an unknown compound using HepaRG cells.  HepaRG cells are a 
differentiated cell line with hepatocyte-like characteristics such as CYP-enzymes and hepatic 
transporters required for the metabolism and disposition of drugs in the liver, which are lacking 
in other hepatoma cell lines such as HepG2 cells.  They also provide opportunity to study 
chronic toxicity of compounds for up to 4 weeks after differentiation, compared to short 
incubation periods offered by other cell models, such as primary hepatocytes or HepG2 cells.   
ABSTRACT 
Using galactose instead of glucose in the culture media of hepatoma cells lines such as HepG2 
cells has been utilised for a decade in order to unmask the mitochondrial liability of chemical 
compounds. We have previously reported a modified glucose-galactose assay on HepG2 cells, 
reducing the experimental period for screening of mitochondrial toxicity to 2 -4 hours. HepaRG 
cells are one of the few cell lines that retain some of the important characteristics of human 
hepatocytes, at the same time as offering advantages of working with a cell line, thus are 
considered as an alternative for HepG2 cells in drug toxicity screening.  We have described a 
method here to use HepaRG cells in an acute metabolic switch assay using specific 
glucose/galactose media for this cell line, a combined ATP-Protein-LDH assay measuring three 
endpoints from one 96 well plate, and the criteria to label a compound as a mitochondrial toxin.     
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INTRODUCTION 
The Crabtree effect (Crabtree 1929), a situation where the energy requirements of a cell can be 
met by glycolysis alongside oxidative phosphorylation (OXPHOS) makes it difficult to detect 
early onset mitochondrial toxicity of drugs in hepatoma-originated cell lines because they are 
able to switch to glycolysis when OXPHOS is compromised (Diaz-Ruiz et al. 2011).  In a 
glucose-rich environment mitochondrial damage is initially masked until ATP produced by 
glycolysis is no longer sufficient to support cell survival leading to a drop in ATP which 
coincides with other indications of cell death. Thus it becomes impossible to distinguish between 
mitochondrial damage as the primary cause or the subsequent effect of the cell toxicity 
(Kamalian et al. 2015).   
Over the last decade the Crabtree effect has been exploited to enable the detection of 
mitotoxicants in vitro (Marroquin et al. 2007). Specifically, cells are deprived of glucose, the 
main substrate of glycolysis, and are instead cultured in an alternative fuel source, galactose, that 
produces a net ATP production close to zero from glycolysis. In this altered environment, drug-
induced mitochondrial dysfunction cannot be masked by glycolytic ATP production (Swiss et al. 
2011).  
In our previous work we introduced an acute metabolic modification assay in HepG2 cells, 
which is a modified short glu/gal assay (Kamalian et al. 2015).  This highly specific method, 
however, suffered from limitations due to a lack, or very low amount, of metabolizing enzymes 
in HepG2 cells, that might give false negative results when investigating drug metabolite-driven 
mitochondrial toxicity. Furthermore, due to the proliferative nature of HepG2 cells, long term 
incubation (> 7 days) of compounds can be difficult to model. HepaRG cells, a hepato-carcinoma 
originated cell line (Gripon et al. 2002), offer an attractive alternative in vitro model due to some 
more hepatocytelike characteristics including more abundant cytochrome P450 (CYP450) 
enzymes, bile canaliculi structures and higher expression of bile acid transporters compared to 
HepG2 cells (Kanebratt et al. 2008, Kanebratt et al. 2008).  Furthermore, once fully 
differentiated, these cells stay in non-proliferative state for up to 4 weeks which can be used for 
studying drugs that only show toxicity after long term incubation (Kamalian et al. 2018). 
In this protocol we have adjusted the HepG2 acute metabolic modification assay to be used on 
HepaRG cells.  After acute metabolic switch using glucose or galactose media specifically 
suitable for HepaRG cells for 2 hours, the compound of interest is added to the cells for a short 
period of 2 hours, before the ATP, LDH and protein level of the cells are measured, which then 
are represented as a percentage of the levels in the vehicle treated group. The compound is 
marked as a potential mitochondrial toxicant if the ATP, LDH and or protein IC50 
concentrations fall within a specific criteria. 
 BASIC PROTOCOL 1 
Acute metabolic switch assay with combined ATP-LDH-protein assay in HepaRG cells 
 
The purpose of this protocol is to make use of Crabtree effect in hepatocyte-like hepatoma cell 
line, HepaRG, in order to screen for drugs with potential direct mitochondria liability.  Briefly, 
cells already exposed to the tested drug for the required duration are incubated in glucose or 
galactose media specifically modified to be suitable for HepaRG cells for 2 hours.  A combined 
ATP-LDH-Protein assay is then performed to measure the mentioned end-points.    
 
Materials 
1. Reagents and Solutions 
1.1. HepaRG growth media (Caltag Medsystems) 
1.1.1. HepaRG base medium (Cat. MIL700) 
1.1.2. HepaRG growth additive (Cat. ADD710) 
1.2. HepaRG differentiation medium (Caltag Medsystems) 
1.2.1. HepaRG base medium (Cat. MIL700) 
1.2.2. HepaRG differentiation additive (Cat. ADD720) 
1.3. HepaRG glucose or galactose media:  
1.3.1. Williams’ medium E powder, w/L-Glutamine w/o Glucose (US Biological Life 
Sciences, Cat. W1105-05) 
1.3.2. D-(+)-Glucose Anhydrous (Fisher Scientific, Cat. G/0500/53) 
1.3.3. D-(+)-Galactose (Sigma, Cat. G5388) 
1.3.4. Insulin (Sigma, Cat. I9278-5ml) 
1.3.5. Hydrocortisone: (Sigma, Cat. H0888) 
1.3.6. Sodium bicarbonate: (Sigma, Cat. S576) 
1.4. Combined ATP-LDH-Protein assay: 
1.4.1. Protein assay: Pierce™ BCA Protein Assay Kit (Thermo-Fisher Scientific, Cat. 
23225) 
1.4.2. ATP assay (Sigma) 
1.4.2.1. Somatic cell ATP releasing reagent (Cat. FL-SAR) 
1.4.2.2. ATP bioluminescent assay kit (Cat. FL-AA) 
1.4.2.3. ATP standard (Cat. FL-AAS) 
1.4.3. LDH assay: Cytotoxicity Detection Kit PLUS (LDH) (Sigma, Cat. 4744934001) 
2. Equipment:  
2.1. HepaRG growth and differentiation: 
2.1.1. Nunc Flask vented (different sizes) (Thermo-Fisher Scientific) 
2.1.2. 96-Well CytoOne® Plate, TC-Treated (STARLAB, Cat. CC7682-7596) 
2.1.3. Standard tissue culture incubator (37oC, 95% humidity, 5% CO2) 
2.2. Combined ATP-LDH-Protein assay: 
2.2.1. Clear, flat bottom 96 well plates (any type) 
2.2.2. White, flat bottom 96 well plates (clear or opaque bottom depending on the type 
of the plate reader available.  
2.2.3. Plate reader (with luminescent, photometric and colorimetric reading capacity) 
Protocol steps—Step annotations 
HepaRG cells growth and differentiation:  
1. Make HepaRG growth or differentiation media: Defrost HepaRG growth or 
differentiation additive (see material section) at room temperature or in a 37 OC water 
bath.  Add the whole content of HepaRG growth or differentiation additive bottle into 
a 500 ml bottle of HepaRG base media and mix.  The complete growth or 
differentiation media is stable for 1 month at 2-8 OC. 
Culture and maintenance of HepaRG cells to full differentiation: 
2. Plate undifferentiated HepaRG cells in wells of a 96 well plate at a cell density of 
9000 cells per well, in HepaRG growth media, according to the manufacturers 
instruction.  
In our experience, HepaRG cells can be plated on collagen- or non-collagen 
coated plates with no effect on final growth and differentiated state.   
Plan your final assay configuration and plate the undifferentiated cell 
according your final experimental plate plan. Figure 1 shows an example of 
plating configuration for assessing 7 concentrations (conc. 1-7) of a test 
compound plus vehicle control (VC) in triplicates.   
3. Change the media twice a week with growth media for two weeks to allow the cells to 
grow to 100 % confluence. 
4. Change the media into a 50%:50% growth:differentiation media for first  media 
change after the growth period is completed, then twice a week with differentiation 
media for two weeks.    
At this point (4 weeks after the initial plating) cells are fully differentiated and 
maintain their non-proliferative state and specific hepatocyte-like 
characteristics for 4 weeks, during which the planned experiments can be 
performed. 
Acute metabolic switch assay:   
1. Prepare HepaRG glucose and galactose media (please refer to REAGENTS AND 
SOLUTIONS section) 
2. Pre-treat HepaRG cells with glucose or galactose media: Remove the media from the 
wells. Wash the wells with 100 µl of PBS once.  Add 50 µl of either glucose or 
galactose media to the corresponding wells according to the planned assay 
configuration. Incubate in a cell culture incubator (37 OC, 95% humidity, 5% CO2) 
for 2 h. 
3. Prepare the drug solutions at twice the desired final concentration of the test 
compound in either glucose or galactose media. 
The volume needed for each test compound solution has to be calculated at 50 
µl per well. 
If the compound stock diluent is DMSO make sure the final concentration of 
dimethyl sulfoxide (DMSO) in the wells would not exceed 0.5% of the final 
volume, because of the toxicity effect of DMSO on cells.   
4. Add the 50 µl of media-compound concentration solution to the corresponding wells 
according to the planned assay configuration.   
5. Incubate the plate in the cell culture incubator (37 OC, 95 % humidity, 5% CO2) for 
the duration required (2-24 h).   
Combined ATP-protein-LDH assay: 
1. Prepare the cell lysate and supernatant plates: Transfer the media from all the wells 
into a fresh clear 96 well plate in the same plate format as the original cell plate. 
Label this plate as supernatant stock (SS) plate. Add 100 µl of Somatic cell ATP 
releasing reagent into each well containing cells. Agitate the plate on a plate shaker 
on medium speed for at least 5 minutes at room temperature. Label this plate as lysate 
stock (LS) plate. Label three clear flat bottom 96 well plates as; P (for protein), LDH-
L (for lysate) and LDH-S (for supernatant). Label a white flat, opaque or clear bottom 
(according to your plate reader requirements) 96 well plate as ATP.  
For protein and ATP assays you will need to produce standard curves by 
running protein and ATP standards alongside the main experiments.  
Therefore you need to consider having enough wells for both your samples 
and standards on the same plate. If the samples cover the whole plates, 
standards can be loaded on separate plates, as long as both sample and 
standard plates are treated the same.  In this case pay attention to label the 
sample and the standard plates carefully and clearly.   
Transfer 10 µl of the LS into the wells of the P, LDH-L and ATP plates. Transfer 50 
µl of the SS into the wells of the LDH-S plate.  
Protein assay:  
1. Load 10 µl of protein standards on the P plate or a separate plate if there is not 
enough wells available on the P plate.   
2. Measure the protein level using Pierce™ BCA Protein Assay Kit, according to the 
manufacturer’s instruction.   
3. Calculate the protein level of each well using the standard curve equation.  
If BCA reagent is not compatible with the compound tested, it is possible to 
measure the protein using Bradford assay reagent.  However, in this case the 
samples might need to be diluted further to make sure the measurements fall 
within the linear part of the standard curve.   
ATP assay 
1. Make up the ATP standards according to the manufacturer instruction.  Load them on 
the ATP plate, or on a separate plate if there is not enough well on the ATP sample 
plate.  
2. Make up the ATP assay mix according to the manufacturer instruction. 
3. Add 50 µl of the ATP assay mix onto all the samples and the standards, shake the 
plate/s briefly on a plate shaker and read immediately using luminescence setting of 
the plate reader.  
4. Calculate the ATP level of each well using the ATP standard curve. 
5. Normalize the ATP level of each well to the protein level of the same well to estimate 
ATP level per each µg protein. 
6. Calculate the average ATP level of the triplicate samples in each drug concentration. 
7. Normalize the average ATP level for each drug concentration to the average 
calculated for the vehicle control using the formula (using the vehicle control in 
glucose and galactose media for each corresponding group). 
 
 
8. Construct the ATP-dose response graph. 
9. Calculate the IC50 concentration. 
LDH assay 
1. Add 40 µl of media into the wells of the LDH-L plate to make the samples 5 times 
diluted.  This is so they remain on the standard curve due to signal saturation Make 
up the LDH reagent according to the manufacturer’s instruction, allowing 50 µl 
volume of the reagent for each well containing sample on LDH-L and LDH-S plates.  
2. Add 50 µl of the LDH reagent to all the lysate and supernatant wells. Cover the plates 
and incubate at room temperature and in a dark place for 30 minutes. 
Always include at least 3 wells containing the media for background 
measurement.  If there is not enough wells on the sample plates, this can be 
done on a separate plate.  
3. Read the absorbance using colorimetric plate reader at 510 nm wavelength.   
Subtract the average of the background measurements from all the lysate and supernatant 
measurements  
4. Calculate the reserved LDH in the lysate using the formula:   
 
 
 
5. Calculate the average LDH level of the triplicate samples in each drug concentration. 
6. Normalize the LDH level for each drug concentration to the average calculated for the 
vehicle control using the formula (using the vehicle control in glucose and galactose 
media for each corresponding group). 
 
  
 
7. Draw the LDH-dose response graph. 
8. Calculate the IC50 concentration. 
Criteria for labelling a compound as a mitochondrial toxin  
A compound is labelled positive mitochondrial toxin if:  
1.  
2. The difference between the ATP-IC50 (Glucose) and ATP-IC50 (Galactose) is 
statistically significant.  
Mitochondria is the first or main target of a compound if: 
1.  
2.  
 
3. The difference between the LDH-IC50 (Galactose) and ATP-IC50 (Galactose) is 
statistically significant.  
 
REAGENTS AND SOLUTIONS 
HepaRG glucose or galactose media:  
1. Reconstitute glucose-free Williams E base media from powder by dissolving 0.88 g 
of the media powder in 80 ml of dH2O. Adjust the pH to 7.4 (the media changes 
colour from yellow to pink), then adjust the volume to 100 ml by adding dH2O. Add 
3.7 mg/ml (w/v) bicarbonate sodium the media and mix well. Filter sterilise the media 
using a 0.22 µm syringe or bottle filter unit. 
2. Make glucose or galactose stock 1 M solutions: Dissolve 1.8 g of glucose or galactose 
powder in 10 ml PBS, then filter sterilize. Aliquot and store at -20OC. 
Galactose might not dissolve in PBS easily, in this case the solution can be 
placed in a sonic bath for 10-20 before filter sterilization.  
3. Prepare hydrocortisone 5.5 mM stock solution:  Dissolve 10 mg of the powder in 1 ml 
of 100 % ethanol. Make-up the volume to 5 ml by Williams’ E glucose free base 
media (see step 1.1.). Aliquot and store at 2 - 8 OC. 
4. To make glucose or galactose media add either glucose (11 mM) or galactose 
(10mM), insulin (5 µg/ml), L glutamine (4 or 6 mM) and hydrocortisone (50 mM) to 
the basal media (the values in the brackets indicate the final concentration of each 
compound). The amounts needed to prepare 10 ml of each media is summarized in 
Table 1.  
The media before addition of additives already contains 2 mM L-glutamine.  
Therefore, additional 2 or 4 mM is added to make the final desired 4 or 6 mM 
in glucose or galactose media respectively.  
The HepaRG glucose or galactose media are stable at least for one week after 
preparation at 2-8 oC, therefore could be prepared in advance.  
 
COMMENTARY 
Critical Parameters and Troubleshooting 
Seeding density of HepaRG cells  
HepaRG cells when differentiated consists of two different cell populations; hepatocyte-like and 
epithelial cell.  The proportion of the two cell types need to stay in a specific ratio in order for 
the cells to retain their specific metabolic characteristics (Aninat et al. 2006, Cerec et al. 2007).  
In order to achieve this, the original seeding density of the cells in different vessels have been 
optimized by the manufacturers (Biopredics).  It is important for this protocol to adhere to those 
seeding density, which for example is 9000 cells per well for a 96 well plate.   
HepaRG glucose and galactose media 
All the ingredients specified in the material section and within the annotated protocol for 
HepaRG glucose and galactose media are required in order to achieve the results expected from 
this protocol.  For example simple glucose free DMEM media supplemented by galactose or 
glucose which is normally used for HepG2 cells will not be suitable for use for HepaRG cells, 
even though the length of incubations on the assay day are short.  Once the glucose or galactose 
media are prepared they are stable for at least one week at 2-8oC.  Therefore these media can be 
prepared in advance, in the interest of speeding the process on the day of the assay.  
Statistical Analyses 
To test the significance of the difference between ATP-IC50 values in glucose and galactose 
media, or ATP-IC50 and LDH IC50 values in galactose medium the authors the test that was 
used by was un-paired student t-test, assuming non-equal variances, comparing the results of at 
least three independent experiments.   
  
Understanding Results 
Comparing results for a compound labelled as a positive mitochondrial toxin, rotenone versus a 
negative compound, digitonin. 
Rotenone (a mitochondrial complex I inhibitor) reduced the ATP level to 50% of the vehicle 
control in galactose media at 0.17 ±0.04 µM.  The ATP in glucose media, and LDH level in 
glucose or galactose media never declined to 50% of the vehicle control.  This resulted in a 
IC50ATPglu/IC50ATPgal and IC50LDHgal/IC50ATPgal ratios of >650 (Table 2).  Both the 
differences were statistically significant.  Conversely, using digitonin (a detergent) the ATP and 
LDH levels in both glucose and galactose media reached 50% of the vehicle at similar 
concentrations.  According to the criteria in section 5 of the protocol, rotenone and digitonin are 
labelled as positive and negative for mitochondrial toxicity.  Figure 1 provides typical dose 
response graphs created for rotenone and digitonin.  
  
Time Considerations 
HepaRG growth and differentiation take four weeks to complete after which cells will stay in 
non-proliferative fully differentiated status for four weeks, during which the protocol can be 
performed.  The acute metabolic switch assay including pre-treatment in glu/gal media, 
incubation with the compounds, and combined protein-ATP-LDH assay is completed in less than 
a working day (5-8 hours depending on the speed of the operator and the preparations that may 
be made beforehand).  
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FIGURE LEGENDS 
Figure 1:  Changes in ATP and LDH levels of HepaRG cells when exposed to rotenone or 
digitonin for 2 hours in either HepaRG glucose or galactose media after being pretreated with the 
same media for 2 hours. Values are reported as percentages of the vehicle control. Figure taken 
from the original manuscript by Kamalian et al https://doi.org/10.1016/j.tiv.2018.08.001, 
 available under the creative commons licence http://creativecommons.org/licenses/by/4.0/.  
 
TABLES 
Table 1:  Summary of the reagents needed for making HepaRG glucose or galactose 
media.   
Ingredient 
Glucose media (10 ml) Galactose media (10 ml) 
Stock  Final  Volume  Stock  Final  Volume  
Glucose 1 M 11 mM 110 µM --- --- --- 
Galactose --- --- --- 1 M 10 mM 100 µM 
Insulin V* 5 µg/ml V* V* 5 µg/ml V* 
L-glutamine 200 mM 4 mM** 100 µM 200 mM 6 mM** 200 µM 
Hydrocortisone 5.5 mM 50 µM 90.8 µl 5.5 mM 50 µM 90.8 µl 
Williams-E N/A N/A 
Up to 10 
ml 
N/A N/A 
Up to 10 
ml 
* V is for variable:  the insulin stock concentration varies from batch to batch, therefore 
the volume needed has to be calculated for each batch separately.   
** Please refer to the notes under “Reagents and Solution” section.  
 
Table 2: The ATP and LDH IC50 values and statistical analysis calculated from dose response 
curves after incubation of HepaRG cells with rotenone or digitonin for 2 hours in glucose or 
galactose media.  Data taken from the original manuscript by Kamalian et al 
https://doi.org/10.1016/j.tiv.2018.08.001, available under the creative commons licence 
http://creativecommons.org/licenses/by/4.0/.  
 
  
IC50-ATP (µM) ± S.D. IC150-LDH
 
(µM) ± S.D. IC50ATPglu/IC50ATPgal 
(p value)* 
IC150LDHgal/IC50ATPgal 
(p value)* Glucose Galactose Glucose Galactose 
Rotenone >100 0.17 ± 0.04 >100 >100 >605 (< 0.001) >605 (< 0.001) 
Digitonin 7.65 ± 1.64 8.82 ± 2.01 
6.80 ± 
0.07 
8.00 ± 2.07 0.87 (0.478) 0.90 (0.646) 
* p value is estimated using unpaired Student t-test, assuming non-equal variances.   
 
 
 
    
 
